After 15 years with JDRF and the T1D Fund and working successfully to implement JDRF’s venture philanthropy’s initiative focused on the development and commercialization of transformative therapies and devices to better treat, prevent and cure type 1 diabetes (T1D), Peter Lomedico recently established a diabetes and venture philanthropy consulting group, Lomed Biomedical Consulting LLC. Lomedico joined JDRF in 2005 to lead the Industry Partnerships Program, an effort to support the transfer of early-stage T1D research and promising translational projects to the commercial sector. Working with JDRF Research this program entered in 89 collaborative partnerships with 57 companies, committed ~$162M JDRF research funding and leveraged company matching funding & follow-on investments >$1B. In 2017 Lomedico transitioned to join JDRF’s T1D Fund - an independently managed venture philanthropy fund involved in early-stage catalytic commercial investments to accelerate life-changing T1D therapies. To date the T1D Fund has ~$100M under management and has invested ~$50M in 23 companies developing T1D therapies and devices. 

Lomedico has a diverse background in molecular biology, diabetes research, and drug discovery, with more than 25 years of pharmaceutical and biotechnology experience. Prior to joining JDRF, he worked at NeoGenesis Pharmaceuticals as vice president of strategic alliances, at CuraGen Corporation as vice president of discovery research, and at Genome Therapeutics Corporation as vice president of human genetics. In addition, Lomedico conducted genomics and drug discovery research in various positions at Hoffmann-LaRoche in New Jersey and Switzerland. Lomedico received his bachelor’s degree in biology from Villanova University, his doctorate in molecular biology from the University of Texas Health Science Center at Houston, and conducted research on insulin genes in the laboratory of Dr. Walter Gilbert at Harvard University with a postdoctoral research fellowship from JDRF.